Abstract

BackgroundCurrent human influenza vaccines lack the adaptability to match the mutational rate of the virus and therefore require annual revisions. Because of extensive manufacturing times and the possibility that antigenic alterations occur during viral vaccine strain production, an inherent risk exists for antigenic mismatch between the new influenza vaccine and circulating viruses. Targeting more conserved antigens such as nucleoprotein (NP) could provide a more sustainable vaccination strategy by inducing long term and heterosubtypic protection against influenza. We previously demonstrated that intranodal mRNA injection can induce potent antigen-specific T-cell responses. In this study, we investigated whether intranodal administration of mRNA encoding NP can induce T-cell responses capable of protecting against a heterologous influenza virus challenge.MethodsBALB/c mice were immunized in the inguinal lymph nodes with different vaccination regimens of mRNA encoding NP. Immune responses were compared with NP DNA vaccination via IFN-γ ELISPOT and in vivo cytotoxicity. For survival experiments, mice were prime-boost vaccinated with 17 µg NP mRNA and infected with 1LD50 of H1N1 influenza virus 8 weeks after boost. Weight was monitored and viral titers, cytokines and immune cell populations in the bronchoalveolar lavage, and IFN-γ responses in the spleen were analyzed.ResultsOur results demonstrate that NP mRNA induces superior systemic T-cell responses against NP compared to classical DNA vaccination. These responses were sustained for several weeks even at low vaccine doses. Upon challenge infection, vaccination with NP mRNA resulted in reduced lung viral titers and improved recovery from infection. Finally, we show that vaccination with NP mRNA affects the immune response in infected lungs by lowering immune cell infiltration while increasing the fraction of T cells, monocytes and MHC II+ alveolar macrophages within immune infiltrates. This change was associated with altered levels of both pro- and anti-inflammatory cytokines.ConclusionsThese findings suggest that intranodal vaccination with NP mRNA induces cross-strain immunity against influenza, but also highlight a paradox of influenza immunity, whereby robust immune responses can provide protection, but can also transiently exacerbate symptoms during infection.

Highlights

  • Current human influenza vaccines lack the adaptability to match the mutational rate of the virus and require annual revisions

  • We evaluated whether intranodally delivered naked messenger RNA (mRNA) can elicit robust T-cell responses against the conserved antigen NP of an H3N2 influenza strain and compared these responses to those obtained through DNA vaccination

  • Intranodal immunization with mRNA induces stronger T‐cell responses compared to intramuscular DNA vaccination Vaccination with DNA encoding conserved influenza antigens has been studied extensively and was shown to induce cross-protective immunity in small animals [27]

Read more

Summary

Introduction

Current human influenza vaccines lack the adaptability to match the mutational rate of the virus and require annual revisions. Protection provided by conventional influenza vaccines depends upon the generation of neutralizing antibody responses against the viral hemagglutinin (HA) and, to some extent, antibodies that can inhibit the viral neuraminidase (NA) activity Such responses can effectively reduce or even prevent influenza and confer herd immunity on a population scale but are largely restricted to the strains included in the vaccine. Influenza vaccine formulations require annual revisions due to the relatively high mutational frequencies that occur within the major antigenic regions of HA and NA through the processes of antigenic drift [4] This requirement, together with a significant production time of several months, forces vaccine manufacturers to rely on predictions of the strain that will most likely circulate in the season, thereby running the risk of developing a mismatched vaccine [5]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call